M
Myron S. Cohen
Researcher at University of North Carolina at Chapel Hill
Publications - 576
Citations - 50913
Myron S. Cohen is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 103, co-authored 549 publications receiving 46021 citations. Previous affiliations of Myron S. Cohen include University of Massachusetts Medical School & Scripps Health.
Papers
More filters
Journal ArticleDOI
The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers
Cynthia Nau Cornelissen,Meera Kelley,Marcia M. Hobbs,James E. Anderson,J G Cannon,Myron S. Cohen,P. Frederick Sparling +6 more
TL;DR: The transferrin receptor mutant was incapable of initiating urethritis, although the same inoculum size of the wild‐type parent strain, FA1090, causes ure arthritis in >90% of inoculated volunteers.
Journal ArticleDOI
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?
Myron S. Cohen,M. Kumi Smith,Kathryn E. Muessig,Timothy B. Hallett,Kimberly A. Powers,Angela D. M. Kashuba +5 more
TL;DR: Evidence is growing that wider, earlier initiation of ART could reduce population-level incidence of HIV, and ongoing community-based prospective trials of early ART are likely to help to establish the population- level benefit of ART, and-if successful-to galvanise treatment as prevention.
Journal ArticleDOI
Monoclonal Antibodies for Prevention and Treatment of COVID-19.
Journal ArticleDOI
Sexual transmission of HIV: infectiousness and prevention.
TL;DR: HIV can be transmitted through contaminated blood and blood products; from a mother to her offspring during pregnancy childbirth or breast feeding; or through sexual contact.
Journal ArticleDOI
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Lawrence Corey,Peter B. Gilbert,Michal Juraska,David C. Montefiori,Lynn Morris,Shelly Karuna,Srilatha Edupuganti,Nyaradzo Mgodi,Allan C. deCamp,Erika Rudnicki,Yunda Huang,Pedro Gonzales,Robinson Cabello,Catherine Orrell,Javier R. Lama,Fatima Laher,Erica Lazarus,Jorge Sanchez,Ian Frank,Juan C Hinojosa,Magdalena E. Sobieszczyk,Kyle E. Marshall,Pamela G Mukwekwerere,Joseph Makhema,Lindsey R. Baden,James I. Mullins,Carolyn Williamson,John Hural,M. Juliana McElrath,Carter Bentley,Simbarashe Takuva,Margarita M. Gomez Lorenzo,David N. Burns,Nicole Espy,April K. Randhawa,Nidhi Kochar,Estelle Piwowar-Manning,Deborah Donnell,Nirupama Sista,Philip Andrew,James G. Kublin,Glenda Gray,Julie E. Ledgerwood,John R. Mascola,Myron S. Cohen,Hvtn,Hptn,Hptn Study Teams +47 more
TL;DR: VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV- 1 isolates provided proof-of-concept that bnAb prophylaxis can be effective.